Anselamimab

Anselamimab has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 4, 2026: “Clearing protein deposits restored liver regrowth in aged mice”.

Intervention

1 paper studies it2 findingsUpdated Nov 1, 2026

1 new paper in 30 daysSee all 1 papers on anselamimab

At a glance

The findings reach mice, none yet in people. 1 lab; 3 trials, none about aging.

None of its findings points the other way.

1 lab
3 trials, none about aging

3 of 3 trials sponsored by its developers

Animals1

What did studies of anselamimab find?

Studies of anselamimab measured 2 outcomes; the most studied are inflammatory gene expression (1 study) and liver regeneration (1).

Inflammatory gene expression

downin mice1

1 study

Anselamimab decreases inflammatory gene expression in mice.
“Single-cell RNA sequencing confirms that anselamimab reverses aging-induced endothelial marker loss and inflammatory gene upregulation.”
Animalsliver endothelium
Clearing protein deposits restored liver regrowth in aged mice
Cell reportsNov 1, 2026

Latest

1 paper in 12 months

Cell ReportsNov 4

Clearing protein deposits restored liver regrowth in aged mice

Experiments in aged mice found that clearing abnormal protein deposits around blood vessels with anselamimab restored liver regeneration after partial liver removal.Experiments in aged mice found that clearing abnormal protein deposits around blood vessels with anselamimab restored liver regeneration after partial liver removal.

Mouse studyInterventions

Paper

Anselamimab

At a glance

What did studies of anselamimab find?

Latest

Clearing protein deposits restored liver regrowth in aged mice

Related